Countries began inoculating their populations in December after the Pfizer/BioNTech vaccine was approved. Other vaccines are now being rolled out across the world, just as a new wave of lockdowns have been brought in to stem a rising tide of Christmas holiday infections.
The success that countries have in their vaccination programs, seen as offering the best way out of the lockdowns and the economic damage they have caused, may become reflected in domestic equity markets, Robeco’s investing and health care experts say.
“Throughout 2020, a key theme for equity investors globally was closely tracking new Covid-19 infections at a country level, which certainly correlated with sentiment shifts in local equity markets,” says Jeroen Blokland, Head of the Multi-Asset team.
“Although investors will no doubt continue to monitor infection rates this year too, we think that vaccination rates will be by far the most important barometer of equity market sentiment in 2021.”
Excitement over the first vaccinations has been tempered with a huge spike in infections that has proved to be worse in places than the initial wave in March 2020. “We’re only a few days into 2021, and yet the prospect of a full return to normal by the autumn already appears to be vanishing over the horizon, unless governments everywhere quickly galvanize public health efforts to vaccinate their populations,” says Richard Purkiss, portfolio manager with the Global Equity team and a qualified medical doctor.
“What’s especially disappointing about this prospect is that we witnessed a ’superhuman’ cooperative effort from medical researchers and pharmaceutical companies to produce not just one but several effective and safe vaccines in quantities large enough to begin to meet the challenge of this pandemic in record time.”
“Yet, we then saw ‘pedestrian’ early vaccination rates by health care agencies in all but a few countries where vaccines have now been approved, suggesting that a return to normal by the end of summer is already looking highly improbable.”
The latest Covid-19 figures are scary. Confirmed infections globally now stand at more than 85 million, and estimates of the likely true infected numbers (including all the unconfirmed or silent infections) are somewhere between 5-10 times greater. That represents around 5-11% of the world population, and presents a major logistical challenge for health authorities, not least as all five currently approved vaccines require two doses, given three weeks apart.
“To be relatively certain of avoiding most of the worst economic impacts of the pandemic by the end of September, the global vaccination rate would need to reach 30 million per day for a vaccine that requires two doses,” says Purkiss.
“Our estimate assumes that herd immunity would begin to kick in at the 70% level of vaccination or infection in the population. This could be relatively optimistic, particularly if either of the recently identified and apparently more transmissible UK or South African variants were to become dominant strains worldwide over 2021.”
Then there is the issue of newer or stronger strains emerging that could prove a challenge for the vaccines’ efficacy. “Even assuming vaccine-resistant strains don’t emerge over the next 12 months, most national strategies will probably still struggle to meet their vaccination targets across the year,” Purkiss warns. “As a consequence, it now seems likely that a significant part of the world at least will still be facing many of the same difficulties and economic restrictions in the first half of 2022.”
“Moreover, given how widely spread this coronavirus now is, it is likely to become endemic, and hence vaccine-resistant strains are likely to emerge at some point in the not so distant future. So, continued close surveillance of this virus will still be required even after this pandemic fades, and the need for updated versions of these newly-approved vaccines is not likely to disappear either, unless we want a repeat of 2020!”
For investors, it means taking a much more cautious approach until there is more clarity, says Blokland, whose team has been taking risk off the table since the severity of the latest outbreak became known.
“As we emphasized in our 2021 Outlook (among other publications), the path to a new normal is likely to be rocky, and hiccups in the distribution of vaccines are to be expected,” Blokland says. “As we received more information on the massive challenge the world is facing to reach herd immunity in recent weeks, we reduced the overall risk exposure of our portfolios late last year.”
“The already formidable task for the vaccine – to build a bridge between the current slowdown and better times later – has become even harder. With equity and corporate bond markets already anticipating better times, rising to new all-time highs in the meantime, the odds of a temporary setback have increased. Hence, we have reduced the weight of these asset classes to neutral.”
However, there is still the prospect of ‘jam tomorrow’ as company earnings recover, backed by continuing stimulus programs while the lockdowns are still in place, he says.
“At this point we do not believe there is enough reason to deviate from our base case scenario – that we continue to believe that massive fiscal and monetary stimulus will allow the global economy to resume its recovery,” Blokland says.
“In this scenario, company earnings are expected to rise by at least 20% this year. Given where equity valuations currently are – high in absolute terms but attractive relative to other asset classes – earnings growth will be the main driver of equity returns, pushing markets higher.”
“However, recent developments regarding both the virus as well as vaccination are hampering visibility on when the recovery will actually resume. This bodes for a more neutral stance in our multi-asset portfolios for now.”
The information contained on these pages is for marketing purposes and solely intended for Qualified Investors in accordance with the Swiss Collective Investment Schemes Act of 23 June 2006 (“CISA”) domiciled in Switzerland, Professional Clients in accordance with Annex II of the Markets in Financial Instruments Directive II (“MiFID II”) domiciled in the European Union und European Economic Area with a license to distribute / promote financial instruments in such capacity or herewith requesting respective information on products and services in their capacity as Professional Clients.
The Funds are domiciled in Luxembourg and The Netherlands. ACOLIN Fund Services AG, postal address: Affolternstrasse 56, 8050 Zürich, acts as the Swiss representative of the Fund(s). UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, acts as the Swiss paying agent. The prospectus, the Key Investor Information Documents (KIIDs), the articles of association, the annual and semi-annual reports of the Fund(s) may be obtained, on simple request and free of charge, at the office of the Swiss representative ACOLIN Fund Services AG. The prospectuses are also available via the website www.robeco.ch. Some funds about which information is shown on these pages may fall outside the scope of the Swiss Collective Investment Schemes Act of 26 June 2006 (“CISA”) and therefore do not (need to) have a license from or registration with the Swiss Financial Market Supervisory Authority (FINMA).
Some funds about which information is shown on this website may not be available in your domicile country. Please check the registration status in your respective domicile country. To view the RobecoSwitzerland Ltd. products that are registered/available in your country, please go to the respective Fund Selector, which can be found on this website and select your country of domicile.
Neither information nor any opinion expressed on this website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco Switzerland Ltd. product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports.